Venrock stays modest with $450M ninth fund as it continues to seek disruptive, early-stage tech 

With its latest $450 million fund, Venrock has eschewed the broader industry trend toward raising record funds, preferring to maintain a modest slate of early-stage investments in first-in-class therapies, genomics platforms and healthcare IT. 

According to the firm’s Bryan Roberts, about half of Venrock 9 will be allocated to healthcare, and the remainder to technology. ...